Cargando…

Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262

BACKGROUND: In many mammals, the duration of the nocturnal melatonin elevation regulates seasonal changes in reproductive hormones such as luteinizing hormone (LH). Melatonin's effects on human reproductive endocrinology are uncertain. It is thought that the same hypothalamic pulse generator ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kripke, Daniel F, Kline, Lawrence E, Shadan, Farhad F, Dawson, Arthur, Poceta, J Steven, Elliott, Jeffrey A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481506/
https://www.ncbi.nlm.nih.gov/pubmed/16704731
http://dx.doi.org/10.1186/1472-6874-6-8
_version_ 1782128250094354432
author Kripke, Daniel F
Kline, Lawrence E
Shadan, Farhad F
Dawson, Arthur
Poceta, J Steven
Elliott, Jeffrey A
author_facet Kripke, Daniel F
Kline, Lawrence E
Shadan, Farhad F
Dawson, Arthur
Poceta, J Steven
Elliott, Jeffrey A
author_sort Kripke, Daniel F
collection PubMed
description BACKGROUND: In many mammals, the duration of the nocturnal melatonin elevation regulates seasonal changes in reproductive hormones such as luteinizing hormone (LH). Melatonin's effects on human reproductive endocrinology are uncertain. It is thought that the same hypothalamic pulse generator may both trigger the pulsatile release of GnRH and LH and also cause hot flashes. Thus, if melatonin suppressed this pulse generator in postmenopausal women, it might moderate hot flashes. This clinical trial tested the hypothesis that melatonin could suppress LH and relieve hot flashes. METHODS: Twenty postmenopausal women troubled by hot flashes underwent one week of baseline observation followed by 4 weeks of a randomized controlled trial of melatonin or matched placebo. The three randomized treatments were melatonin 0.5 mg 2.5–3 hours before bedtime, melatonin 0.5 mg upon morning awakening, or placebo capsules. Twelve of the women were admitted to the GCRC at baseline and at the end of randomized treatment for 24-hour sampling of blood for LH. Morning urine samples were collected twice weekly to measure LH excretion. Subjective responses measured throughout baseline and treatment included sleep and hot flash logs, the CESD and QIDS depression self-ratings, and the SAFTEE physical symptom inventory. RESULTS: Urinary LH tended to increase from baseline to the end of treatment. Contrasts among the 3 randomized groups were statistically marginal, but there was relative suppression combining the groups given melatonin as contrasted to the placebo group (p < 0.01 one-tailed, Mann-Whitney U = 14.) Similar but not significant results were seen in blood LH. There were no significant contrasts among groups in hot flashes, sleep, depression, or side-effect measures and no significant adverse effects of any sort. CONCLUSION: The data are consistent with the hypothesis that melatonin suppresses LH in postmenopausal women. An effect related to the duration of nocturnal melatonin elevation is suggested. Effects of melatonin on reproductive endocrinology should be studied further in younger women and in men. Larger studies of melatonin effects on postmenopausal symptoms would be worthwhile.
format Text
id pubmed-1481506
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14815062006-06-22 Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262 Kripke, Daniel F Kline, Lawrence E Shadan, Farhad F Dawson, Arthur Poceta, J Steven Elliott, Jeffrey A BMC Womens Health Research Article BACKGROUND: In many mammals, the duration of the nocturnal melatonin elevation regulates seasonal changes in reproductive hormones such as luteinizing hormone (LH). Melatonin's effects on human reproductive endocrinology are uncertain. It is thought that the same hypothalamic pulse generator may both trigger the pulsatile release of GnRH and LH and also cause hot flashes. Thus, if melatonin suppressed this pulse generator in postmenopausal women, it might moderate hot flashes. This clinical trial tested the hypothesis that melatonin could suppress LH and relieve hot flashes. METHODS: Twenty postmenopausal women troubled by hot flashes underwent one week of baseline observation followed by 4 weeks of a randomized controlled trial of melatonin or matched placebo. The three randomized treatments were melatonin 0.5 mg 2.5–3 hours before bedtime, melatonin 0.5 mg upon morning awakening, or placebo capsules. Twelve of the women were admitted to the GCRC at baseline and at the end of randomized treatment for 24-hour sampling of blood for LH. Morning urine samples were collected twice weekly to measure LH excretion. Subjective responses measured throughout baseline and treatment included sleep and hot flash logs, the CESD and QIDS depression self-ratings, and the SAFTEE physical symptom inventory. RESULTS: Urinary LH tended to increase from baseline to the end of treatment. Contrasts among the 3 randomized groups were statistically marginal, but there was relative suppression combining the groups given melatonin as contrasted to the placebo group (p < 0.01 one-tailed, Mann-Whitney U = 14.) Similar but not significant results were seen in blood LH. There were no significant contrasts among groups in hot flashes, sleep, depression, or side-effect measures and no significant adverse effects of any sort. CONCLUSION: The data are consistent with the hypothesis that melatonin suppresses LH in postmenopausal women. An effect related to the duration of nocturnal melatonin elevation is suggested. Effects of melatonin on reproductive endocrinology should be studied further in younger women and in men. Larger studies of melatonin effects on postmenopausal symptoms would be worthwhile. BioMed Central 2006-05-16 /pmc/articles/PMC1481506/ /pubmed/16704731 http://dx.doi.org/10.1186/1472-6874-6-8 Text en Copyright © 2006 Kripke et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kripke, Daniel F
Kline, Lawrence E
Shadan, Farhad F
Dawson, Arthur
Poceta, J Steven
Elliott, Jeffrey A
Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262
title Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262
title_full Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262
title_fullStr Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262
title_full_unstemmed Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262
title_short Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262
title_sort melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial nct00288262
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481506/
https://www.ncbi.nlm.nih.gov/pubmed/16704731
http://dx.doi.org/10.1186/1472-6874-6-8
work_keys_str_mv AT kripkedanielf melatonineffectsonluteinizinghormoneinpostmenopausalwomenapilotclinicaltrialnct00288262
AT klinelawrencee melatonineffectsonluteinizinghormoneinpostmenopausalwomenapilotclinicaltrialnct00288262
AT shadanfarhadf melatonineffectsonluteinizinghormoneinpostmenopausalwomenapilotclinicaltrialnct00288262
AT dawsonarthur melatonineffectsonluteinizinghormoneinpostmenopausalwomenapilotclinicaltrialnct00288262
AT pocetajsteven melatonineffectsonluteinizinghormoneinpostmenopausalwomenapilotclinicaltrialnct00288262
AT elliottjeffreya melatonineffectsonluteinizinghormoneinpostmenopausalwomenapilotclinicaltrialnct00288262